Study of patients with iron deficiency and HF in Ireland: prevalence and treatment budget impact.

Autor:	Wong B; Irish Clinical Academic Fellow in Cardiology Cardiology Department, Connolly Hospital, Dublin 15, Ireland., Redmond S; Health Economic Specialist and Managing Director of Salutem Insights Salutem Insights, www.saluteminsights.com., Blaine C; Cardiology Specialist Nurse Cardiology Department, Connolly Hospital, Dublin 15, Ireland., Nugent CA; Cardiology Specialist Nurse Cardiology Department, Connolly Hospital, Dublin 15, Ireland., Saiva L; Cardiology Registrar Cardiology Department, Connolly Hospital, Dublin 15, Ireland., Buckley J; Cardiology Specialist Registrar Cardiology Department, Connolly Hospital, Dublin 15, Ireland., O'Neill J; Cardiology Consultant in Heart Failure Cardiology Department, Connolly Hospital, Dublin 15, Ireland.
Jazyk:	angličtina
Zdroj:	The British journal of cardiology [Br J Cardiol] 2021 Mar 09; Vol. 28 (1), pp. 10. Date of Electronic Publication: 2021 Mar 09 (Print Publication: 2021).
DOI:	10.5837/bjc.2021.010
Abstrakt:	This study aims to present the screening, prevalence and treatment of heart failure (HF) patients with iron deficiency in an Irish hospital and use an economic model to estimate the budget impact of treating eligible patients with intravenous ferric carboxymaltose (IV FCM). Retrospective data were collected on 151 HF patients over a one-year period from all newly referred HF patients to a secondary care hospital. This included 36 patients with preserved ejection fraction (HFpEF) and 115 with reduced ejection fraction (HPrEF). An existing budget impact model was adapted to incorporate Irish unit cost and resource use data to estimate the annual budget impact of treating patients with IV FCM. The total number of HFrEF patients who met criteria for iron replacement was 44 (38% of total HFrEF patients); of this, only nine (20%) were treated. The budget impact model estimates that treating all eligible patients with IV FCM in this single centre would save 40 bed-days and over €7,600/year. To improve the quality of life and reduce hospitalisation, further identification and treatment of iron deficient patients should be implemented. Expanding the use of IV iron nationally would be cost and bed saving. Competing Interests: None declared. (Copyright © 2021 Medinews (Cardiology) Limited.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu